ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Citing portfolio reassessment, two drug companies are returning pharmaceutical development rights to biotech partners. Merck & Co. has returned Parkinson’s drug candidates to Addex Pharmaceuticals, the Swiss firm that discovered them. Addex says it will continue to develop the drugs, known as allosteric modulators. Genzyme, meanwhile, has returned non-U.S. rights for ataluren, a treatment for muscular dystrophy and cystic fibrosis, to PTC Therapeutics. PTC already had U.S. rights to the drug, which is in clinical trials.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X